scholarly journals Increasing Synaptic GluN2B levels within the Basal and Lateral Amygdala Enables the Modification of Strong Reconsolidation Resistant Fear Memories

2019 ◽  
Author(s):  
Christopher A. de Solis ◽  
Cuauhtémoc U. Gonzalez ◽  
Mario A. Galdamez ◽  
John M. Perish ◽  
Samuel W. Woodard ◽  
...  

AbstractReconsolidation disruption has been proposed as a method to attenuate pathological memories in disorders such as PTSD. However, studies from our group and others indicate that strong memories are resistant to becoming destabilized following reactivation, rendering them impervious to agents that disrupt the re-stabilization phase of reconsolidation. Thus, therapies designed to attenuate maladaptive memories by disrupting reconsolidation updating have not been adequately developed. We previously determined that animals possessing strong auditory fear memories, compared to animals with weaker fear memories, are associated with an enduring increase in the synaptic GluN2A/GluN2B ratio in neurons of the mouse basal and lateral amygdala (BLA). In this study, we determined whether increasing GluN2B levels within BLA excitatory neuronal synapses is sufficient to enable modification of strong fear memories via reconsolidation. To accomplish this, we utilized a combinatorial genetic strategy to express GluN2B or GluN2B(E1479Q) in excitatory neurons of the mouse BLA before or after fear memory consolidation. GluN2B(E1479Q) contains a point mutation that increases synaptic expression of the subunit by interfering with phosphorylation-driven endocytosis. At the time of memory retrieval, increasing synaptic GluN2B levels by expression of GluN2B(E1479Q), but not GluN2B(WT), enhanced the induction of reconsolidation rendering the strong fear memory modifiable. GluN2B(WT) or GluN2B(E1479Q) expression did not influence fear memory maintenance or extinction. Fear memory consolidation, however, was enhanced when GluN2B(E1479Q) was expressed in the BLA at the time of training. These findings indicate that enhancing GluN2B synaptic trafficking may provide a novel therapeutic strategy to enhance modification of pathological memories.

2009 ◽  
Vol 65 ◽  
pp. S233
Author(s):  
Hiroshi Nomura ◽  
Koichi Hashikawa ◽  
Norio Matsuki

PLoS ONE ◽  
2011 ◽  
Vol 6 (5) ◽  
pp. e19958 ◽  
Author(s):  
Melissa S. Monsey ◽  
Kristie T. Ota ◽  
Irene F. Akingbade ◽  
Ellie S. Hong ◽  
Glenn E. Schafe

2013 ◽  
Vol 26 (3) ◽  
pp. 468-478 ◽  
Author(s):  
Hadley C. Bergstrom ◽  
Craig G. McDonald ◽  
Smita Dey ◽  
Gina M. Fernandez ◽  
Luke R. Johnson

2011 ◽  
Vol 19 (1) ◽  
pp. 9-14 ◽  
Author(s):  
C. F. Gavin ◽  
M. D. Rubio ◽  
E. Young ◽  
C. Miller ◽  
G. Rumbaugh

2010 ◽  
Vol 68 ◽  
pp. e405
Author(s):  
Natsuko Imamura ◽  
Norio Matsuki ◽  
Hiroshi Nomura

2001 ◽  
Vol 120 (5) ◽  
pp. A685-A685
Author(s):  
B SINGH ◽  
V MALMSTROM ◽  
F POWRIE

2020 ◽  
Vol 26 ◽  
Author(s):  
Maryam Dashtiahangar ◽  
Leila Rahbarnia ◽  
Safar Farajnia ◽  
Arash Salmaninejad ◽  
Arezoo Gowhari Shabgah ◽  
...  

: The development of recombinant immunotoxins (RITs) as a novel therapeutic strategy has made a revolution in the treatment of cancer. RITs are resulting from the fusion of antibodies to toxin proteins for targeting and eliminating cancerous cells by inhibiting protein synthesis. Despite indisputable outcomes of RITs regarding inhibiting multiple cancer types, high immunogenicity has been known as the main obstacle in the clinical use of RITs. Various strategies have been proposed to overcome these limitations, including immunosuppressive therapy, humanization of the antibody fragment moiety, generation of immunotoxins originated from endogenous human cytotoxic enzymes, and modification of the toxin moiety to escape the immune system. This paper devoted to reviewing recent advances in the design of immunotoxins with lower immunogenicity.


Sign in / Sign up

Export Citation Format

Share Document